WallStreetZenWallStreetZen

NASDAQ: TRML
Tourmaline Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for TRML

Based on 4 analysts offering 12 month price targets for Tourmaline Bio Inc.
Min Forecast
$48.00+200%
Avg Forecast
$61.00+281.25%
Max Forecast
$74.00+362.5%

Should I buy or sell TRML stock?

Based on 4 analysts offering ratings for Tourmaline Bio Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TRML stock forecasts and price targets.

TRML stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-25
lockedlocked$00.00+00.00%2024-03-20
lockedlocked$00.00+00.00%2024-03-20
lockedlocked$00.00+00.00%2023-10-31

1 of 1

Forecast return on equity

Is TRML forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is TRML forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

TRML revenue forecast

What is TRML's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$60.0M
Avg 2 year Forecast
$60.0M
Avg 3 year Forecast
$48.6M

TRML vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRML$16.00$61.00+281.25%Strong Buy
TVTX$5.39$12.20+126.35%Buy
ANNX$4.59$16.20+252.94%Strong Buy
TRDA$12.36$21.00+69.90%Buy
LRMR$6.33$20.00+215.96%Strong Buy

Tourmaline Bio Stock Forecast FAQ

Is Tourmaline Bio Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: TRML) stock is to Strong Buy TRML stock.

Out of 4 analysts, 3 (75%) are recommending TRML as a Strong Buy, 1 (25%) are recommending TRML as a Buy, 0 (0%) are recommending TRML as a Hold, 0 (0%) are recommending TRML as a Sell, and 0 (0%) are recommending TRML as a Strong Sell.

If you're new to stock investing, here's how to buy Tourmaline Bio stock.

What is TRML's revenue growth forecast for 2025-2027?

(NASDAQ: TRML) Tourmaline Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Tourmaline Bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TRML's revenue for 2025 to be $1,538,790,540, with the lowest TRML revenue forecast at $1,538,790,540, and the highest TRML revenue forecast at $1,538,790,540. On average, 1 Wall Street analysts forecast TRML's revenue for 2026 to be $1,538,790,540, with the lowest TRML revenue forecast at $1,538,790,540, and the highest TRML revenue forecast at $1,538,790,540.

In 2027, TRML is forecast to generate $1,246,420,337 in revenue, with the lowest revenue forecast at $841,205,495 and the highest revenue forecast at $1,538,790,540.

What is TRML's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: TRML) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is TRML's Price Target?

According to 4 Wall Street analysts that have issued a 1 year TRML price target, the average TRML price target is $61.00, with the highest TRML stock price forecast at $74.00 and the lowest TRML stock price forecast at $48.00.

On average, Wall Street analysts predict that Tourmaline Bio's share price could reach $61.00 by Mar 25, 2025. The average Tourmaline Bio stock price prediction forecasts a potential upside of 281.25% from the current TRML share price of $16.00.

What is TRML's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: TRML) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.